(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
Prolonged use of topical corticosteroids may increase intraocular pressure, with resultant glaucoma, damage to the optic nerve, and defects in visual acuity and fields of vision. However, data from 2 uncontrolled studies 1-2 indicate that in patients with increased intraocular pressure and in those susceptible to a rise in intraocular pressure upon application of topical corticosteroids, there is less effect on pressure with HMS® (medrysone 1% liquifilm opthalmic) than with dexamethasone or betamethasone.
Prolonged use of topical corticosteroids may rarely be associated with development of posterior subcapsular cataracts.
General: With prolonged use of HMS® (medrysone 1% liquifilm opthalmic) , the intraocular pressure and the lens should be examined periodically. In persistent corneal ulceration where a corticosteroid has been used, or is in use, fungal infection should be suspected.
Pregnancy Category C: Medrysone has been shown to be embryocidal in rabbits when given in doses 10 and 30 times the human dose. Medrysone was ocularly applied to both eyes of pregnant rabbits 2 drops 4 times per day on day 6 through 18 of gestation. A significant increase in early resorptions was observed in the treated rabbits. There are no adequate or well-controlled studies in pregnant women. Medrysone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional HMS Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.